Eyenuk has secured $26 million in a Series A financing round, bringing the company's total funding to over $43 million.
Eyenuk will use the capital to expand its AI product platform with additional disease indications and advanced care coordination, and to accelerate the platform's global commercialization and adoption.
Eyenuk's platform enables automated AI diagnosis and coordination of care. Since its FDA clearance in 2020, the EyeArt system has been used in over 200 locations in 18 countries, including 14 U.S. states, to screen more than 60,000 patients. The company said it is the first and only technology to be cleared by the FDA for autonomous detection of both referable and vision-threatening diabetic retinopathy without any eye care specialist involvement.
The EyeArt system is reimbursed by Medicare in the US, and has regulatory approvals globally, including CE Marking, Health Canada license, and approvals in multiple markets in Latin America and the Middle East.
